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OBJECTIVES This study was designed to examine whether myocarditis induced in a mouse model can be
effectively suppressed by nasal administration of cardiac myosin (CM).
BACKGROUND Myocarditis in humans often follows viral infection and is accompanied by evidence of an
autoimmune response to CM. Treatment has been hampered by the fact that measures
undertaken to reduce the autoimmune response often enhance the viral infection. Delivery of
antigen via nasal route has been shown to induce antigen-specific tolerance and suppress
certain autoimmune diseases in animal models.
METHODS Myocarditis was induced in A/J mice by two subcutaneous injections of CM emulsified in
complete Freund’s adjuvant. Nasal instillation of CM (200 mg/mouse) or vehicle buffer was
carried out three days before the first subcutaneous injection (day 23). The effect of nasal
instillation of CM on cardiac histopathology, cytokine production by splenocytes, and
antibody response was examined three weeks after the first subcutaneous injection (day 21).
RESULTS Nasal administration of CM effectively reduced the severity of myocarditis. Consistent with
the histological findings, the levels of interleukin-2 (IL-2), tumor necrosis factor-a, and
IL-1b produced by splenocytes in response to CM were significantly decreased. In addition,
the serum levels of IgE and IgG1 anti-myosin antibodies were suppressed. However, the
levels of transforming growth factor-b (TGF-b) and CM-specific IgA antibodies were not
affected.
CONCLUSIONS Taken together, our results do not support active suppression through upregulation of
TGF-b, IL-4, and IL-10 as a mechanism of tolerance, but favor anergy or deletion of both
Th1 and Th2 autoreactive T cells. (J Am Coll Cardiol 2000;36:1992–9) © 2000 by the
American College of Cardiology
Myocarditis in humans often follows infection by cox-
sackieviruses of group B3 and is accompanied by evidence of
an autoimmune response to cardiac myosin (CM) (1).
Efforts at treatment have been hampered by the fact that
measures undertaken to reduce the autoimmune response
often enhance the viral infection (2). An approach designed
to achieve antigen-specific immunosuppression without im-
pairing the anti-viral immunity would be beneficial. In a
mouse model, we have shown that myocarditis can be
induced by immunization with either murine cardiac myo-
sin (MCM) or porcine cardiac myosin (PCM) (3,4). The
cardiac lesions induced by MCM or PCM closely resemble
those of human myocarditis. Myosin-induced myocarditis is
a T-cell-dependent disease; however, antibodies have been
shown to transfer the disease in some mouse strains (5–7).
The role of Th1 and Th2 cytokines in the pathogenesis of
autoimmune myocarditis is unclear, although tumor necro-
sis factor-a (TNF-a) has been implicated as an important
mediator of disease (8,9).
Mucosal administration of antigens has been described as
a method to induce antigen-specific tolerance and suppress
autoimmune diseases in several animal models, including
experimental autoimmune encephalomyelitis (EAE), exper-
imental autoimmune myasthenia gravis (EAMG), experi-
mental allergic uveoretinitis, insulin-dependent diabetes
mellitus, and collagen-induced arthritis (10,11). Depending
on the amount of antigen fed, the orally administered
antigens can either induce regulatory cells that suppress the
immune response through the local production of cytokines
or can silence antigen-specific T cells by induction of clonal
anergy or clonal deletion.
Recently, nasal administration of antigen has been re-
ported as an alternative route to induce mucosal tolerance in
some experimental autoimmune models (12–15). The nasal
administration of antigen often appears to be more effective
than oral administration in inducing tolerance (16). This
difference can be explained by the fact that the antigen
delivered via the nasal route is less likely to be degraded by
acid and proteolytic enzymes that are present in the gastro-
intestinal environment. It was demonstrated that antigen
given orally in milligram doses or nasally in microgram
doses to Lewis rats prior to immunization with acetylcho-
line receptor (AChR) similarly prevented clinical signs of
EAMG and suppressed AChR-specific B- and T-cell-
mediated immune response (17).
In this study, we examined whether nasal administration
of CM is effective in suppressing the induction of experi-
mental autoimmune myocarditis in mice. We also investi-
gated the effect of nasal instillation of CM on the cytokine
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profiles and antibody response, and we discuss the possible
mechanisms underlying the suppression of the disease.
METHODS
Induction of myocarditis. Myocarditis was induced in
four- to five-week-old female A/J mice, which were ob-
tained from the Jackson Laboratory (Bar Harbour, Maine)
and maintained in the conventional animal facility at the
Johns Hopkins School of Medicine. The PCM was ex-
tracted from pig ventricular muscle and MCM from pooled
mouse hearts using the procedure as described previously
(18). The purified CM was emulsified with equal volume of
complete Freund’s adjuvant (CFA; Sigma, St. Louis, Mis-
souri) supplemented with 5 mg/ml of Mycobacterium tuber-
culosis H37Ra. Each mouse was injected subcutaneously
with 100 ml of the emulsion containing 200 mg of CM on
day 0 and day 7. Control mice were given the same amount
of emulsion containing CFA and vehicle buffer (0.5 mol/
liter KCl, pH 6.8) without myosin. On day 0, each mouse
including the control mice also received an intraperitoneal
injection of 500 ng of pertussis toxin (List Biological
Laboratories, Campbell, California).
Nasal administration of antigen. Nasal administration of
antigen was carried out by intranasal intubation three days
prior to the first subcutaneous injection of CM. A fine,
flexible plastic tubing (outside diameter 0.03 in. [0.08 cm]
VWR), which was connected to a Hamilton syringe
through a 27-gauge needle, was gently inserted 5 mm into
a nostril of a mouse under metofane anesthesia. Approxi-
mately 50 ml of CM or vehicle buffer (0.5 mol/liter KCl, pH
6.8) was slowly instilled into each mouse.
Histopathology. All mice were euthanized on day 21. The
hearts were rapidly removed, fixed in 10% phosphate buff-
ered formalin, and then embedded in paraffin. Serial sec-
tions were made through a portion of the heart. Every fifth
section was placed on a slide and stained with hematoxylin
and eosin. Evidence of myocarditis was determined blindly
by two pathologists using a light microscopy according to a
four-tier scoring system: Grade 1 corresponding to cardiac
infiltration of approximately up to 10% of the cardiac
sections; Grade 2, 11% to 20%; Grade 3, 21% to 40%;
Grade 4, greater than 40%. The average score from the two
pathologists’ readings was used for statistical analysis.
T-Cell proliferation assay and in vitro cytokine produc-
tion by splenocytes. On day 21, the spleen of each mouse
was teased into a single-cell suspension in RPMI-1640
(Life Technologies, Grand island, New York) using forceps.
The splenic cells were sedimented and washed twice with
15 ml of fresh RPMI-1640 by centrifugation at 1,300 rpm
(352 g) for 8 min. The viable cells were counted by
trypan blue exclusion, and suspended at 1 3 106 cells/ml
in RPMI-1640 medium supplemented with 10% fetal
calf serum (Life Technologies), 15 mmol/liter HEPES, 1%
L-glutamine, 1% MEM vitamins, 1% nonessential amino
acids, 0.1 mmol/liter b-mercaptoethanol, 1% sodium pyru-
vate, and 100 U/ml of penicillin-streptomycin. Then
100 ml/well of the cell suspension was dispensed into a
96-well U-bottom microtiter plate, which had already
been loaded with 100 ml of the diluted antigen. Serial
dilutions were made of CM ranging from 4.0 mg/ml to
0.25 mg/ml. Each plate also contained wells with medium
alone or concanavalin A (ConA) as negative or positive
controls, respectively. Each sample was tested in quadrupli-
cate. The plates were incubated at 37°C in a humidified
CO2 incubator for 96 h, and then pulsed with 1 mCi/well of
[3H]-thymidine (Amersham, Piscataway, New Jersey). Af-
ter 18 h, the cells were harvested onto a piece of glass
microfiber filter paper. The radioactivity was recorded using
a Matrix-96 Direct beta-counter. The stimulation index
was calculated by dividing the mean [3H]-thymidine incor-
poration of myosin-stimulated cultures by the mean [3H]-
thymidine incorporation of cultures with medium alone.
For in vitro cytokine production, the viable splenocytes
were cultured at 5 3 106 well of a 24-well plate in
RPMI-1640 complete medium in the presence of CM at
10 mg/ml. For each mouse, wells containing medium alone
and ConA were also included as negative and positive
controls. The plates were incubated at 37°C in a humidified
CO2 incubator. After 48 h, the supernatant was collected,
aliquoted and frozen at 280°C for cytokine measurements
as described below.
Quantitation of cytokines by ELISA. The levels of inter-
leukins (IL)-2, IL-4, IL-10, IL-1bs, interferon-g (IFN-g),
TNF-a, and transforming growth factor-b (TGF-b) were
measured by Quantikine cytokine ELISA kits (R & D
Systems, Minneapolis, Minnesota) according to the manu-
facturer’s instructions. Each sample was tested in duplicate.
The optical densities were obtained using an ELISA reader
(Dynatech Laboratories, Chantilly, Virginia) at dual wave-
lengths of 450 nm and 570 nm. The quantity of each
cytokine was calculated from the standard curve of the
cytokine included on each plate. For every mouse, the level
of each cytokine produced by splenocytes in the wells with
medium alone was subtracted from that produced in re-
sponse to myosin or ConA.
Abbreviations and Acronyms
AChR 5 acetylcholine receptor
CM 5 cardiac myosin
CFA 5 complete Freund’s adjuvant
ConA 5 concanavalin A
EAE 5 experimental autoimmune encephalomyelitis






MCM 5 murine cardiac myosin
PCM 5 porcine cardiac myosin
TGF-b 5 transforming growth factor-b
TNF-a 5 tumor necrosis factor-a
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Detection of serum levels of anti-CM antibodies by
ELISA. Flat-bottom 96-well microtiter plates were coated
with 100 ml/well of CM at 5 mg/ml in bicarbonate buffer
(pH 9.6). The plates were incubated in a damp box and
incubated at 4°C overnight. The next day, the plates were
blocked with 100 ml/well of phosphate-buffered saline
(PBS), pH 7.2, containing 1% bovine serum albumin (BSA)
and 0.05% Tween-20 (PBS/BSA/Tween), and incubated at
37°C for 1 h. After washing three times with PBS contain-
ing 0.05% Tween-20 (PBS/Tween), the plates were loaded
with 100 ml/well of diluted serum samples. Each sample was
tested in duplicate. The serum samples were diluted in
PBS/BSA/Tween 1:400 for detection of total IgG antibod-
ies, 1:200 for detection of IgG1, IgG2a, and IgG2b iso-
types, and 1:50 for IgA antibodies. Each plate contained the
same positive and negative control serum samples. The
plates were incubated with sera overnight at 4°C in a
damp box. On the third day, the plates were washed three
times with PBS/Tween and incubated at 37°C for 1 h with
100 ml/well of peroxidase-conjugated goat anti-mouse sec-
ondary antibodies diluted to 1:1000 for IgG (KPL, Gaith-
ersburg, Maryland), 1:500 for IgG1, IgG2a (Pharmingen,
San Diego, California), IgG2b (Bethyl, Montgomery,
Texas) and IgA (Sigma, St. Louis, Missouri). Finally, after
three additional washes with PBS/Tween, plates were
loaded with 100 ml/well of 3,39,5,59-tetramethylbenzidine
substrate solution and incubated at room temperature for
about 5 to 15 min. The color reaction was stopped by
adding 100 ml of 1 mol/liter sulfuric acid. The optical
density (OD) values were determined by an ELISA reader
at 450 nm wavelength. Results were expressed as the
adjusted ODs [5Sample OD reading 3 100/(OD of
positive control 2 OD of negative control)]. Serum con-
centrations of total IgE were determined using anti-mouse
IgE capture and detection antibodies (Pharmingen, San
Diego, California) according to the protocol recommended
by the manufacturer. The concentration of IgE of each
testing sample was read off the IgE standard curve.
Statistical analysis. Statistical differences in the levels of
cytokines and antibodies were determined using the Mann-
Whitney U test. A p value of , 0.05 was considered
significant.
RESULTS
Intranasal administration of CM reduced the severity of
autoimmune myocarditis. Autoimmune myocarditis was
induced in A/J mice by two subcutaneous immunizations on
days 0 and 7 with either PCM or MCM in CFA. To
determine whether nasal administration of CM can prevent
the induction of myocarditis, we first administered 200
mg/mouse of PCM intranasally to A/J mice either once on
day 23, twice on days 23, and 14, or three times on days
23, 14, and 112. We found that a single nasal instillation
of PCM three days prior to the first immunization (day 23)
effectively reduced the severity of myocarditis on day 21
(Fig. 1A), as compared with the positive control mice that
received vehicle buffer intranasally. In the positive control
group, 6 of 14 mice developed myocarditis. The severity of
disease of the six mice ranged from 1 to 4, with an average
of 2.3 (Fig. 1B). In the treatment group, only one of nine
mice was found to have a small focal cardiac infiltrate, which
was less than 5% of the total heart section (Fig. 1C). Two
and three nasal instillations did not appear to be more
effective than a single administration in suppressing the
induction of the disease.
The experiment was repeated using MCM instead of
PCM for both nasal instillation and subcutaneous immuni-
zation. Nasal administration of MCM also significantly
reduced the severity of myocarditis on day 21 (p 5 0.048,
Fig. 1A). In the positive control group of 10 mice that
received vehicle buffer intranasally, 6 developed severe
myocarditis with more than 30% of the heart infiltrated
(grades 3–4), and the rest developed mild to moderate
disease. The average disease severity was 3.0. However, in
the treatment group of nine mice that received MCM
intranasally, only one developed severe myocarditis (grade
4); five developed mild to moderate disease; and three had
no disease. The average disease severity was 1.0. Thus, nasal
instillation of cardiac myosin can effectively reduced the
severity of autoimmune myocarditis in mice.
Intranasal administration of CM suppressed the produc-
tion of IL-2, TNF-a and IL-1b by splenocytes. To
examine the changes in cytokine profile in response to
intranasal administration of CM, splenocytes were collected
on day 21 from mice that were treated intranasally with
PCM or that were treated with vehicle buffer, and cultured
in vitro in the presence of PCM or ConA. The levels of
various cytokines produced in the culture supernatants
including IL-2, IFN-g, IL-4, IL-10, TNF-a, IL-1b, and
TGF-b were then measured. All of these cytokines were
detectable in the supernatants of splenocytes cultured in the
presence of PCM, with the levels of IFN-g being the
highest, IL-2, TNF-a, and TGF-b being the moderate,
and IL-10, IL-4, and IL-1b being the lowest. As shown in
Figure 2, mice that were treated with PCM intranasally
generated significantly lower levels of IL-2 in response to
PCM than did control mice treated intranasally with buffer
(p 5 0.048). However, the levels of IL-2 produced in
response to ConA were the same in mice that received
PCM intranasally and that received buffer intranasally,
indicating there was no general suppression of the immune
response (Fig. 2).
In mice that received PCM intranasally, the levels of
TNF-a (p 5 0.04) and IL-1b (p 5 0.02) produced in
response to PCM were also significantly reduced, in com-
parison with control mice receiving buffer intranasally (Fig.
2). Although the levels of other cytokines such as IFN-g
and IL-10 were also lower in mice that received PCM
intranasally, the decrease was not found to be statistically
significant. In addition, there was no apparent difference in
the levels of IL-4 (data not shown) and TGF-b (Fig. 3)
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between control mice that received buffer intranasally and
mice that received CM intranasally.
In the parallel experiment where MCM was used instead
of PCM for nasal instillation and subcutaneous immuniza-
tion, the levels of aforementioned cytokines were also
measured and compared between mice that were treated
intranasally with and without MCM. All the cytokines
listed above except IL-1b and IL-4 were detected, and the
overall levels of detectable cytokines were generally lower
than those detected in the experiment where PCM was used
as antigen. Nevertheless, in line with the above findings, the
levels of IL-2 and TNF-a were markedly decreased in mice
that were treated with MCM intranasally compared with
those that received vehicle buffer intranasally. Therefore,
nasal instillation of CM had caused a significant decrease in
the levels of IL-2, TNF-a, and IL-1b, correlating with the
suppression of the disease.
We also examined the effect of nasal instillation of cardiac
myosin on T-cell proliferative response. Splenocytes were
collected on day 21 and cultured in the presence of varying
doses of cardiac myosin or ConA. In the positive control
mice that received buffer intranasally, it was found that the
average stimulation index to CM was about 2 to 3 and the
average stimulation index to ConA was about 25. In mice
that received CM intranasally, the stimulation indices to
CM and ConA were similar to those of the positive control
Figure 1. Nasal administration of CM reduced the severity of autoimmune myocarditis. (A) Female A/J mice were immunized subcutaneously twice on
days 0 and 7 with porcine or murine CM (PCM or MCM) in complete Freund’s adjuvant for the induction of myocarditis. Three days prior to the first
subcutaneous immunization with PCM (day 23), one group of mice (n 5 9, open triangles) received a single nasal instillation of PCM, and the positive
control group (n 5 14, filled triangles) received equal volume of vehicle buffer. Three days prior to the first subcutaneous immunization with MCM, one
group of mice (n 5 9, open circles) received a single nasal administration of MCM, and the positive control group (n 5 10, filled circles) received vehicle
buffer only. All mice were sacrificed on day 21 when the heart sections were examined for evidence of myocarditis using the grading system described in
the Methods section. The difference in severity between mice that received MCM intranasally and those that received vehicle buffer intranasally was
statistically significant (p 5 0.048). (B) Heart section from a PCM-immunized positive control mouse that received buffer intranasally and developed
moderate myocarditis (grade 2.5) (24 3 magnification). The inset on the top right corner is a closeup image (240 3 magnification) of the cardiac infiltrate.
(C) Heart section from the only mouse that developed cardiac infiltration in the group that received intranasal instillation of PCM (24 3 magnification).
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mice. Thus, nasal instillation of CM did not suppress T-cell
proliferation to either CM or ConA.
Intranasal administration of CM caused a decrease in the
serum levels of IgE and anti-myosin antibodies of IgG1
subclass. To investigate the effect of nasal instillation of
cardiac myosin on the humoral response, the serum levels of
IgE and PCM-specific antibodies including IgA, IgG, and
its subclasses IgG1, IgG2a and IgG2b were measured. Sera
were collected on day 10 and day 21 to measure antibody
levels postimmunization. Levels of the antibodies were
compared between mice that received PCM intranasally and
those that received buffer intranasally. As shown in Figure 4,
mice that received PCM intranasally had markedly lower
levels of IgE on both day 10 and day 21 than mice that
received buffer intranasally. The decrease in IgE was more
pronounced on day 10 (p 5 0.01). Moreover, the levels of
PCM-specific IgG1 antibodies on both day 10 (p 5 0.04)
and day 21 (p 5 0.04) were significantly reduced in mice
that received PCM intranasally, compared to those that
received buffer intranasally (Fig. 5). Although the levels of
IgG, IgG2a, and IgG2b anti-PCM antibodies were also
slightly lower in mice that were treated intranasally with
PCM, the decrease was not statistically significant. Further-
more, the levels of PCM-specific IgA antibodies were
comparable between mice that received PCM nasally and
those that received buffer nasally. Thus, nasal instillation of
CM significantly reduced the serum levels of IgE and
myosin-specific IgG1 antibodies, correlating with disease
suppression.
DISCUSSION
In the present study, our results demonstrate that CM
administered intranasally to A/J mice can effectively sup-
Figure 2. Nasal administration of CM suppressed production of IL-2, TNF-a, and IL-1b by splenocytes in response to CM. Upon sacrifice on day 21,
the spleens were collected from mice that received cardiac myosin intranasally (right bars, n 5 9) and those that received vehicle buffer (left bars, n 5 14).
The splenocytes were cultured in vitro in the presence of either CM (10 mg/ml) or concanavalin A (ConA). The levels of cytokines produced in the culture
supernatant were measured after 48 h and presented as the mean of each group 6 SEM. The levels of IL-2 (p 5 0.048), TNF-a (p 5 0.04), and IL-1b
(p 5 0.02) produced in response to CM were significantly decreased in mice that received CM intranasally, compared to those that received buffer
intranasally. The levels of IL-2 produced in response to ConA were not reduced after nasal instillation of myosin.
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press the induction of murine autoimmune myocarditis.
The suppression of disease correlated with significant re-
duction in the levels of IL-2, TNF-a, and IL-1b, and in the
serum levels of IgE and IgG1 anti-myosin antibodies. No
increase was observed in the levels of TGF-b, and serum
IgA anti-myosin antibodies.
Possible mechanisms that underlie the suppression of
disease. The mechanisms of mucosal tolerance have been
extensively studied in other autoimmune disease models,
particularly in EAE. Two major mechanisms have been
proposed based on the dose of the antigen administered
orally (10,11). Repeated low doses of antigen favor the
generation of regulatory cells secreting cytokines, such as
TGF-b, IL-4 and IL-10, which antagonize the develop-
ment of a Th1 response. In contrast, a single high dose of
antigen causes the deletion or anergy of both Th1 and Th2
autoreactive T cells. Recent studies on nasal tolerance in
autoimmune models, particularly in EAMG, suggested that
tolerance could be induced via similar mechanisms (19).
To understand the possible mechanisms that underlie the
suppression of autoimmune myocarditis, we examined the
effect of nasal administration of CM on the balance of Th1
(IL-2, IFN-g) and Th2 (IL-4, IL-10) cytokines, on the
production of TGF-b, TNF-a, and IL-1b, and on the
antibody response. Our results showed that the levels of
IL-2, a prototypic Th1 cytokine, were significantly lower in
mice that received myosin intranasally compared to the
control mice that received buffer intranasally. The reduction
in the levels of IL-2 was specific to CM stimulation because
no decrease was observed upon ConA stimulation. When
we measured the serum levels of IgE and myosin-specific
IgG1 antibodies, a significant decrease occurred in mice that
received myosin intranasally as compared to the control
mice receiving buffer intranasally. Because the isotype
switch to IgE and IgG1 is known to be driven by IL-4
(20,21), the reduction in IgE and IgG1 anti-myosin anti-
bodies in mice that received myosin intranasally may indi-
cate the downregulation of IL-4, which is the prototypic
Th2 cytokine. We were unable to show a significant
decrease in the levels of IL-4 produced by splenocytes. This
may be due to the fact that the levels of IL-4 were at the
limit of detection and the method used was not sensitive
enough to demonstrate the reduction.
In addition, we also observed a significant reduction in
the levels of TNF-a and IL-1b produced by splenocytes
from mice that received intranasal instillation of CM. This
is consistent with our previous finding that high levels of
TNF-a are strongly associated with the development of
myocarditis upon immunization with CM (4). Further-
more, it is interesting to mention that TNF-a is a cytokine
Figure 3. Nasal administration of CM did not reduce the production of
TGF-b by splenocytes in response to CM. The splenocytes from mice that
received either CM (right bar, n 5 4) or vehicle buffer (left bar, n 5 3)
intranasally were cultured in vitro in the presence of CM (10 mg/ml). The
levels of TGF-b produced in the culture supernatant were measured and
presented as the mean of each group 6 SEM. There was no decrease in the
levels of TGF-b observed in mice that received CM nasally as compared to
those that received buffer nasally.
Figure 4. Nasal administration of CM reduced the serum levels of total IgE antibodies. Sera were collected on days 10 and 21 from mice that received CM
intranasally (right bars, n 5 9) and those that received vehicle buffer (left bars, n 5 14). The serum levels of total IgE antibodies (ng/ml) were measured by a
capture ELISA and presented as the mean of each group 6 SEM. The levels of IgE were lower in mice that received CM intranasally on both days 10 and 21,
compared to those that received buffer. The decrease in IgE levels on day 10 was statistically significant (p 5 0.01).
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that can be produced during both Th1 and Th2 immune
responses (22). Thus, these results do not favor a mecha-
nism of immune deviation from Th1 response to Th2
response, but rather suggest clonal anergy or deletion of
both Th1 and Th2 autoreactive T cells. At present, we do
not know if this effect is dose-related. Future studies of
applying multiple lower doses of CM intranasally would be
useful. Despite the reduced production of cytokines by
spleen cells, we did not detect a significant decrease in
T-cell proliferation to varying doses of CM in mice that
received CM intranasally. This may be attributed to the
likelihood that T-cell proliferative response is not a sensitive
measure of T-cell activation in our model. This is supported
by the observation that splenic T cells from myocarditic
mice can transfer disease to irradiated naı¨ve mice (unpub-
lished results) and produce high levels of various cytokines
when stimulated in vitro with CM, even though they do not
proliferate well to the autoantigen. The disease development
is much better correlated with cytokine production rather
than T-cell proliferation to CM (4).
The role of TGF-b in the suppression of disease. The
role of TGF-b in mediating mucosal tolerance is contro-
versial. Evidence shows that orally administered antigen can
generate populations of cells secreting TGF-b in the gut-
associated lymphoid tissue, and these cells are capable of
regulating the development of Th1 responses (10). It has
also been shown that in vivo blocking of TGF-b by
anti-TGF-b antibodies abolished the tolerance induction
by nasal administration of AChRs in murine model of
myasthenia gravis (23). However, the role of TGF-b in
mediating oral tolerance has recently been challenged by the
report of successful induction of oral tolerance in TGF-b
null mice (24), indicating an alternative mechanism of
tolerance. In our study, we did not observe any increase in
the levels of TGF-b in mice that received CM intranasally.
Our findings that the serum levels of myosin-specific IgA
antibodies were not elevated in mice that received myosin
nasally further argue against the role of TGF-b in the
induction of nasal tolerance, because TGF-b is known to be
a switch factor for IgA production (25). Taken together, our
results do not support active suppression through produc-
tion of TGF-b, IL-4, and IL-10 as a mechanism of
tolerance, but favor anergy or deletion of both Th1 and Th2
autoreactive T cells.
Relevance to human myocarditis. The appropriate treat-
ment of myocarditis in humans remains a major clinical
problem (2). In general, immunosuppressive therapy is
not effective, although some patients clearly benefit from
it. These conflicting results may be attributed to the
likelihood that many cases represent a mixture of virus-
induced and immune-mediated myocarditis. An ap-
proach designed to reduce the immunopathological ef-
fects without impairing the development of anti-viral
immunity would be beneficial in treating this or other
infection-associated autoimmune disorders. The present
evidence shows that the disease can be specifically re-
duced by nasal administration of antigen before the onset
of the autoimmune disease without impairing the general
immune response. Future studies will be directed to nasal
treatment instituted after immunization.
In addition, studies are underway to test the effect of nasal
treatment with cardiac myosin on CB3 virus-induced
chronic myocarditis in mice. Because other heart antigens,
such as adenine nucleotide translocator, branched chain
ketoacid dehydrogenase, sarcoplasmic reticulum calcium
ATPase, and laminin have also been implicated in experi-
mental as well as clinical myocarditis (26–29), it would be
interesting to study whether nasal administration of those
autoantigens has any impact on viral myocarditis.
Figure 5. Nasal administration of CM reduced the serum levels of myosin-specific IgG1 antibodies. The levels of anti-myosin antibodies of the IgG1
subclass were measured in serum samples collected on both days 10 and 21 from mice that received CM nasally (right bars, n 5 9) and from those that
received buffer (left bars, n 5 14). The antibody levels are presented as the mean of adjusted optical densities (adjusted ODs, see Methods section) of each
group 6 SEM. The levels of IgG1 anti-myosin antibodies were significantly reduced in mice that received CM intranasally on both day 10 (p 5 0.04) and
day 21 (p 5 0.04), compared to the control mice that received buffer nasally.
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